MXC: $0.048
Doctors

Doctors are very important to MGC Pharmaceuticals, because they are the gateway to our patients.

Our Doctors have the most influence on the integration of Phytocannabinoid therapy into our world’s existing scope of treatments. That’s why MGC Pharma strives to educate doctors about Medical Cannabis and the Endo-Cannabinoid system, in order to facilitate new and innovative solutions for patients that offer relief from many of today’s prevalent diseases.

Doctors' Access

In MGC Pharma’s Doctor access point, doctors can discover information about Medical Cannabis and engage with MGC in order to become authorised prescribers in certain countries. They can also familiarise themselves with MGC’s R&D and clinical pipelines in order to understand the changes that will be coming with the inclusion of Phytocannabinoid medications within the existing treatment spectrum.

Sign up to receive information on how to prescribe Medicinal Cannabis in Australia, Science, Regulation and the industry as a whole.


Webinars
ASX: MXC
$0.048
Wednesday, 26 September 2018
Latest Announcements
25/9/18Suspension from Official Quotation 25/9/18Contract Default Notice Issued To Varm Cosmo 21/9/18Trading Halt 6/9/18MXC Signs Major Distribution Agreement for GMP Products 3/9/18Appendix 4E and Audited 2018 Financial Report 27/8/18MXC to Commence Australian Dementia Trial with Notre Dame 8/8/18Harvey Nichols Expands MGC Derma Distribution in the UK
Subscribe for news

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
Malta
Czech Republic
Botanical Research and Development Project
UK
European Corporate Headquarters
Israel
Pharma Scientific Board
Who
What
Where
Why